白皮书

Discovery Series #3 – LRRK2

Emerging Targets in Parkinson’s Disease: Leucine-rich repeat kinase 2 (LRRK2)-targeted therapies for the treatment of Parkinson’s disease

Atuka is pleased to present the third entry in our Discovery Series on Emerging Targets in Parkinson’s Disease, examining leucine-rich repeat kinase 2 (LRRK2) as a route toward disease-modifying therapy in Parkinson’s disease (PD).

Authored by Atuka’s co-founder Dr. Michael Hill, this review surveys the biology, clinical pipeline, and translational challenges of LRRK2-targeted therapeutics, and argues that the field has moved from a question of target validation to one of translational optimization: how best to modulate LRRK2 safely and durably across a biologically diverse patient population.

Why LRRK2?

A Mechanistic Hub, Not a Narrow Genetic Target
LRRK2 sits at the intersection of several PD-relevant processes, including vesicular trafficking, lysosomal and autophagic function, mitochondrial homeostasis, and immune signalling. All pathogenic mutations converge on a gain-of-function increase in kinase activity and downstream Rab GTPase phosphorylation. Because elevated LRRK2 activity is also detected in subsets of idiopathic PD, the target’s relevance extends well beyond mutation carriers.
A Heterogeneous Disease Behind a Single Label
“LRRK2-PD” represents a biological spectrum rather than a single disease entity, with substantial variability in penetrance, age of onset, progression, and α-synuclein and tau pathology. The key question for model selection becomes which aspect of LRRK2-linked biology a model captures, which calls for a mechanism-led rather than label-led approach.
A Pipeline That Maps the Open Questions
Small-molecule kinase inhibitors, brain-selective designs, targeted protein degraders, and RNA-based approaches are all advancing in parallel. That diversity reflects unresolved questions about how best to modulate LRRK2 across tissues, disease stages, and biological contexts, and offers a way to read the translational design space.

您将了解到的内容

LRRK2 Biology and Mechanism
How pathogenic mutations drive Rab hyperphosphorylation and propagate across autophagy-lysosomal, synaptic, mitochondrial, and neuroinflammatory pathways, and why these mechanisms are not confined to mutation carriers.
The Clinical and Preclinical Landscape
A program-by-program overview spanning CNS-penetrant kinase inhibitors (Denali/Biogen’s BIIB122, Neuron23’s NEU-411, Brenig’s BT-267), a PROTAC degrader (Arvinas’ ARV-102), and antisense approaches (Biogen’s BIIB094, SciNeuro’s SNP-614), set against the LUMA Phase 2b readout and the MJFF LITE collaborative program.
Safety as a Translational Design Constraint
Why LRRK2 safety is best understood as a function of how the target is modulated, including peripheral on-target effects in lung and kidney observed preclinically, and how brain-selective, degrader, and RNA-based modalities reshape the benefit–risk question.
The Strategic Role of Non-Human Primates
Where NHP studies add the most value, deployed selectively to resolve CNS-versus-peripheral exposure, durability of target engagement, modality-dependent effects, and biomarker relationships relevant to human studies, in line with 3Rs principles.

下载完整报告

LRRK2-targeted therapies for the treatment of Parkinson’s disease
A detailed review of LRRK2 biology, the current therapeutic pipeline, and the translational considerations that will determine whether mechanistic validation becomes clinical benefit.

赋能您的研发项目

联系我们

获取来自 Atuka 的最新科学进展

订阅我们的季刊，了解帕金森疾病研究领域的最新进展。